Ankh Life Sciences Limited

Brian Scott Johnathan Blagg

Gene H Zaid

Cameron E West

Vishal Chandrakumar Birar

Novel compounds which inhibit DYRK1A activity comprise thymoquinone derivatives including a pair of substituted or unsubstituted six-membered carbon rings selected from phenyl and cyclohexadiene linked by an alkyl or alkenyl linker. Each six-membered ring includes at least one oxygen-bearing substituent selected from carbonyl oxygens, hydroxyls, alkoxyls, and halogenated derivatives thereof. The compounds can be administered to mammalian subjects for inhibition of DYRK1A kinase proteins.

Inhibition of DYRK1A kinase

Novel fused tricyclic or bicyclic dimers, such as &#x3b2;-carboline and quinoline moieties with a central linker, exhibit anti-cancer activities against a variety of human cancer cell lines. The dimer compounds can be used in anti-cancer therapeutic compositions useful in the treatment of human cancers.

Growing community of inventors

Niles, MI, United States of America

Brian Scott Johnathan Blagg